Pharmaceutical composition for preventing or treating muscle disease, comprising licochalcone a as active ingredient
The use of Licochalcone A in a pharmaceutical composition addresses the limitations of current muscle disease treatments by promoting muscle cell proliferation and differentiation, effectively preventing and treating muscle diseases through enhanced muscle function and reduced muscle loss.
Patent Information
- Application Number
- PCT/KR2023/018533
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-13
- Filing Date
- 2023-11-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments for muscle diseases are limited, and accurate diagnosis is challenging due to the diverse causes and varying symptoms of these diseases, leading to rapid progression and significant muscle loss, especially in aging populations.
A pharmaceutical composition containing Licochalcone A as an active ingredient that promotes myoblast proliferation, myotube formation, and differentiation into muscle cells, thereby addressing muscle diseases such as muscular atrophy, dystrophy, sarcopenia, and myopathy by suppressing myostatin expression and promoting creatine kinase activity.
The composition effectively prevents and treats muscle diseases by enhancing muscle cell proliferation and differentiation, improving muscle function and reducing muscle loss, as demonstrated by increased muscle diameter and protein expression in mouse models and cell culture analyses.
Smart Images

Figure KR2023018533_28112024_PF_FP_ABST
Abstract
Description
Pharmaceutical composition for preventing or treating muscle disease containing licochalcone A as an active ingredient
[0001] The present invention relates to a pharmaceutical composition for preventing or treating muscle disease, comprising licochalcone A as an active ingredient.
[0002] Muscle is a crucial component of the human body, originating from mesoderm stem cells. Responsible for approximately 40% of our body mass, muscles are located and supported by bones and tendons. Composed of bundles of muscle fibers, they move together and change cell size, triggering contraction. Muscles are categorized as skeletal, cardiac, and visceral, each generating force and inducing movement. They also protect organs such as bones, joints, and internal organs. Furthermore, muscle possesses regenerative capacity. When damaged, satellite cells and their surrounding environment can regenerate muscle, allowing it to regenerate and regain its original contraction and relaxation abilities.
[0003] Muscle diseases are caused by inherited genetic or environmental factors. With the recent trend of an aging society and longer lifespans, diseases related to muscle loss are on the rise. Human muscle mass declines by more than 1% annually after age 40, and by age 80, 50% of peak muscle mass has been lost. Therefore, muscle loss in old age is recognized as the most significant cause of overall decline in physical function. The incidence of these muscle diseases is on the rise worldwide compared to the past.
[0004] However, muscle diseases have diverse causes compared to other conditions, making accurate diagnosis challenging. Symptoms and severity vary depending on the type. Furthermore, many rare diseases have unknown mechanisms. Muscle diseases progress rapidly, and patients often struggle to function independently as their condition progresses. However, treatments for the underlying underlying conditions remain scarce.
[0005] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating muscle disease, which contains licochalcone A as an active ingredient.
[0006] Another object of the present invention is to provide a health functional food composition for preventing or improving muscle disease, which contains Licochalcone A as an active ingredient.
[0007] Another object of the present invention is to provide a reagent composition for promoting differentiation of myoblasts or muscle stem cells into muscle cells, which comprises licochalcone A as an active ingredient.
[0008] Another object of the present invention is to provide a method for promoting differentiation of myoblasts or muscle stem cells into muscle cells, comprising a step of treating a non-human subject with Licochalcone A.
[0009] To achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating muscle disease, which comprises licochalcone A as an active ingredient.
[0010] In addition, the present invention provides a health functional food composition for preventing or improving muscle disease, which contains Licochalcone A as an active ingredient.
[0011] In addition, the present invention provides a reagent composition for promoting differentiation of myoblasts or muscle stem cells into muscle cells, which contains Licochalcone A as an active ingredient.
[0012] In addition, the present invention provides a method for promoting differentiation of myoblasts or muscle stem cells into muscle cells, comprising a step of treating a non-human organism with Licochalcone A.
[0013] According to the present invention, it has been confirmed that licochalcone A inhibits the expression of myostatin and promotes proliferation of myoblasts, myotube formation, and differentiation into muscle cells, thereby being useful as a composition for preventing, treating, or improving muscle diseases; or a composition for promoting differentiation of myoblasts or muscle stem cells into muscle cells.
[0014] Figure 1 shows the results of analyzing the interaction between licochalcone A (hereinafter referred to as Lic A), myostatin (hereinafter referred to as MSTN), and ACVRIIB (Activin receptor type-2B). Figure 1A is the MSTN+Lic A complex, Figure 1B is the MSTN+ACVRIIB complex, and Figure 1C is the MSTN+Lic A+ACVRIIB complex.
[0015] Figure 2 shows the results of analyzing the effects of Lic A on normal muscle tissue and muscle stem cells. Specifically, Figure 2A shows the results of measuring muscle diameter after staining muscle tissue derived from a mouse model orally treated with Lic A, Figures 2B and 2C show the results of analyzing the protein expression of muscle-related factors in the muscle tissue using tissue immunohistochemistry and Western blot, respectively, and Figure 2D shows the results of analyzing the gene and protein expression of muscle-related factors using real-time PCR and Western blot after culturing mouse-derived muscle stem cells in a medium containing Lic A for 2 days. All experimental results are expressed as the mean ± standard deviation (Mean ± SD) (n = 6). *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.
[0016] Figure 3 shows the results of analyzing the effect of Lic A on muscle cell proliferation. Specifically, Figure 3A shows the results of analyzing cell proliferation using MTS analysis of muscle cells cultured in a proliferation medium containing Lic A, and Figure 3B shows the results of analyzing the gene and protein expression of muscle-related factors in the muscle cells using real-time PCR (PCR) and Western blot. All experimental results are expressed as the mean ± standard deviation (Mean ± SD) (n ≤ 35). *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.
[0017] Figure 4 shows the results of analyzing the effect of Lic A on muscle cell differentiation. Specifically, Figure 4A shows the results of analyzing the protein expression of muscle-related factors in muscle cells cultured in a differentiation medium containing Lic A using immunofluorescence staining, Figure 4B shows the results of analyzing creatine kinase activity in the muscle cells, and Figure 4C shows the results of analyzing the gene and protein expression of muscle-related factors in the muscle cells using real-time PCR and Western blot. All experimental results are expressed as the mean ± standard deviation (Mean ± SD) (n ≤ 35). *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.
[0018] Figure 5 shows the results of analyzing the effect of Lic A on the proliferation of aged muscle cells. Specifically, Figure 5A shows the results of MTS analysis on cell proliferation of aged muscle cells treated with Lic A, Figure 2B shows the results of real-time PCR analysis on the gene expression of muscle-related factors in the muscle cells, and Figure 2B shows the results of Western blot analysis on the protein expression of muscle-related factors in the muscle cells. All experimental results are expressed as the mean ± standard deviation (Mean ± SD) (n ≤ 35). *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.
[0019] Figure 6 shows the results of analyzing the effects of licochalcone C (hereinafter referred to as Lic C) on muscle cell proliferation and differentiation. Specifically, Figure 6A shows the results of analyzing cell proliferation of muscle cells cultured in a proliferation medium containing Lic C using MTS analysis, and the results of analyzing creatine kinase activity of muscle cells cultured in a differentiation medium containing Lic C. All experimental results are expressed as the mean ± standard deviation (Mean ± SD) (n ≤ 35). *P ≤ 0.05, **P ≤ 0.001, ***P ≤ 0.0001.
[0020] Hereinafter, the present invention will be described in more detail.
[0021]
[0022] The present invention provides a pharmaceutical composition for preventing or treating muscle disease, comprising licochalcone A as an active ingredient.
[0023] The above licochalcone A can promote myoblast proliferation, myotube formation, or differentiation into muscle cells.
[0024] Additionally, the above licochalcone A can promote creatine kinase activity.
[0025] Additionally, the licochalcone A can promote the expression of one or more selected from the group consisting of Ki67, Cyclin A2, MYL2 (myosin light chain 2) and myosin heavy chain, but is not limited thereto.
[0026] In addition, the licochalcone A can inhibit the expression of one or more selected from the group consisting of myostatin, Atrogin 1, ACVRIIB (Activin receptor type-2B) and MuRF (muscle RING-finger protein-1), but is not limited thereto.
[0027] The above muscle disease may be one or more selected from the group consisting of muscular atrophy, muscular dystrophy, sarcopenia, myopathy, myasthenia, and muscular injury, but is not limited thereto.
[0028] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by placing it in a multi-dose container by formulating it using a pharmaceutically acceptable carrier according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains.
[0029] The pharmaceutically acceptable carriers mentioned above are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
[0030] In the present invention, the content of the additive included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.
[0031] The above pharmaceutical composition may be formulated in the form of one or more external skin preparations selected from the group consisting of injectable formulations such as aqueous solutions, suspensions, emulsions, pills, capsules, granules, tablets, creams, gels, patches, sprays, ointments, ointments, lotions, liniments, pastes, and cataplasmas, but is not limited thereto.
[0032] The pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable carriers and diluents for formulation. The pharmaceutically acceptable carriers and diluents include, but are not limited to, excipients such as starch, sugar, and mannitol; fillers and extenders such as calcium phosphate; cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose; binders such as gelatin, alginates, and polyvinyl pyrrolidone; lubricants such as talc, calcium stearate, hydrogenated castor oil, and polyethylene glycol; disintegrants such as povidone and crospovidone; and surfactants such as polysorbates, cetyl alcohol, and glycerol. The pharmaceutically acceptable carriers and diluents may be biologically and physiologically compatible with the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents, and / or dispersion media.
[0033] The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method. In the case of oral administration, it may be formulated as tablets, troches, lozenges, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups, elixirs, etc. In the case of parenteral administration, it may be formulated as injections, suppositories, powders for respiratory inhalation, aerosols for sprays, ointments, powders for application, oils, creams, etc.
[0034] The dosage of the pharmaceutical composition of the present invention may vary depending on the patient's condition, weight, age, sex, health status, dietary constitution, nature of the formulation, severity of the disease, administration time of the composition, administration method, administration period or interval, excretion rate, and drug form, and may be appropriately selected by a person skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg / kg, but is not limited thereto, and may be administered once or several times a day in divided doses.
[0035] The pharmaceutical composition may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method. The pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time, administration route, etc. of the pharmaceutical composition. A person skilled in the art can easily determine and prescribe an effective dosage for the intended treatment. The pharmaceutical composition of the present invention may be administered once a day or divided into several doses.
[0036]
[0037] In addition, the present invention provides a health functional food composition for preventing or improving muscle disease, which contains Licochalcone A as an active ingredient.
[0038] The present invention can be generally used as a commonly used food.
[0039] The food composition of the present invention can be used as a health functional food. The term "health functional food" refers to a food manufactured and processed using raw materials or ingredients with functional properties useful to the human body as defined in the Health Functional Food Act. "Functionality" refers to ingestion for the purpose of obtaining beneficial effects for health purposes, such as regulating nutrients for the structure and function of the human body or physiological effects.
[0040] The above health functional food composition may contain conventional food additives, and its suitability as the above “food additive” is determined by the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additive Code approved by the Ministry of Food and Drug Safety, unless otherwise specified.
[0041] Items listed in the above “Food Additives Code” include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high-molecular-weight pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents for noodles, preservative preparations, and tar color preparations.
[0042] The food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. For example, among health functional foods in capsule form, hard capsules can be manufactured by mixing and filling a composition according to the present invention with additives such as excipients into a conventional hard capsule, and soft capsules can be manufactured by mixing a composition according to the present invention with additives such as excipients and filling a capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative, etc., as necessary.
[0043] The definitions of terms for the above excipients, binders, disintegrants, lubricants, flavoring agents, etc. are described in literature known in the art and include those with identical or similar functions. There are no specific restrictions on the type of food, and all health functional foods in the conventional sense are included.
[0044] In the present invention, the term “prevention” refers to any act of suppressing or delaying muscle disease by administering a composition according to the present invention.
[0045] In the present invention, the term “treatment” refers to any act of improving or beneficially changing the symptoms of a muscle disease by administering a composition according to the present invention.
[0046] In the present invention, the term “improvement” means any act of improving the bad condition of muscle disease by administering or ingesting the composition of the present invention to a subject.
[0047]
[0048] In addition, the present invention provides a reagent composition for promoting differentiation of myoblasts or muscle stem cells into muscle cells, which contains Licochalcone A as an active ingredient.
[0049]
[0050] In addition, the present invention provides a method for promoting differentiation of myoblasts or muscle stem cells into muscle cells, comprising a step of treating a non-human organism with Licochalcone A.
[0051] Hereinafter, to aid understanding of the present invention, examples will be given in detail. However, the following examples are intended only to illustrate the scope of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of average skill in the art.
[0052]
[0053] [Experimental Example 1] In silico analysis
[0054] The 3D structure of MSTN (myostatin) (PDB ID: 3HH2) was obtained from protein data. After removing heteroatoms and water molecules, the MSTN monomer was prepared using Discovery Studio 2021 (DS) for further molecular docking studies. Auto Dock 4.2 was used to dock the selected compounds into the active site of MSTN. In addition, the 3D structure of ACVRIIB (Activin receptor type-2B) (PDB ID: 1S4Y) was retrieved and used for protein-protein interaction (PPI) studies with MSTN. PPI studies between MSTN and ACVRIIB and the complex of ACVRIIB and MSTN-Lic A were performed using the PatchDock web server, and refinement and ranking were performed using FireDock. The best poses of the complexes (MSTN-Lic A and MSTN-ACVRIIB-Lic A) were used for the final analysis, and the visualization tools PyMOL and DS were used to perform all visual evaluations of the docking results.
[0055]
[0056] [Experimental Example 2] Mouse Experiment
[0057] C57BL / 6 male mice (6 weeks old) were purchased from Hyochang Science. To determine the effects of Lic A on muscle, 6-week-old mice were administered Lic A (3 mg / kg) once daily for 11 days. After 11 days, gastrocnemius muscle and plasma were collected.
[0058]
[0059] [Experimental Example 3] Phalloidin Staining
[0060] The cells of the gastrocnemius muscle and plasma collected in Experimental Example 2 above were fixed with 4% formaldehyde for 10 minutes, washed with physiological saline, and stained with phalloidin (1:400). Thereafter, they were observed using a fluorescence microscope equipped with a digital camera.
[0061]
[0062] [Experimental Example 4] H&E Staining and Muscle Fiber Diameter Analysis
[0063] The gastrocnemius muscle (muscle sections) collected in the above experimental examples were embedded in paraffin, deparaffinized using xylene, rehydrated using a gradient of ethanol concentrations, and stained with H&E (hematoxylin & eosin). The sections were then observed under an optical microscope and photographed at a 400x magnification. The diameters of the muscle fibers were measured using Image J software.
[0064]
[0065] [Experimental Example 5] Tissue Immunohistochemistry
[0066] Paraffin-embedded muscle tissues were deparaffinized with xylene and ethanol, respectively, and then hydrated. To stop endogenous peroxidase activity, the tissues were soaked in 0.3% H2O2 / methanol for 15 minutes. Afterwards, they were stained with H&E for morphological observation or reacted with the tissues for 1 hour at room temperature to block reactions with nonspecific antibodies with 1% normal goat serum, and then reacted with the primary antibody (1:50) for more than 16 hours at 4°C. After 16 hours, they were washed three times with PBS (phosphate buffer saline) and reacted with the secondary antibody (1:100) conjugated with HRP (horse radish peroxidase) for 1 hour at room temperature. Protein expression was observed under a microscope by adding HRP-labeled streptavidin.
[0067]
[0068] [Experimental Example 6] Tissue Immunohistochemistry
[0069] Paraffin-embedded muscle tissues were deparaffinized with xylene and ethanol, respectively, and after rehydration, the tissues were soaked in 0.3% H2O2 / methanol for 15 minutes to stop endogenous peroxidase activity. Afterwards, they were stained with H&E for morphological observation or reacted with the tissues for 1 hour at room temperature to block the reaction with nonspecific antibodies with 1% normal goat serum, and then reacted with primary laminin antibody (1:50) for more than 16 hours at 4°C. After 16 hours, the tissues were washed three times with PBS (phosphate buffer saline) and left incubated with secondary antibody (Alexa Fluor 594 goat anti-Mouse SFX kit) for 1 hour. After 1 hour, the antibody was removed, the cells were washed with PBS for 10 minutes, the nuclei were stained with DAPI (4′,6-diamidino-2-phenylindol), and protein expression was observed using a fluorescence microscope.
[0070]
[0071] [Experimental Example 7] Isolation of mouse muscle stem cells
[0072] The gastrocnemius muscle of 6-week-old C57BL / 6 mice was harvested, minced, and digested with 1% pronase enzyme at 37°C for 1 hour, followed by centrifugation at 1,000 g for 3 minutes. After centrifugation, the supernatant was discarded, and the tissue was suspended in a medium containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin (P / S) in Dulbecco's Modified Eagle's Medium (DMEM), and the tissue and cell layer were separated using a 100 μm strainer. The separated cell layer was centrifuged at 1,000 g for 5 minutes, the formed supernatant was discarded, and the cell layer was suspended by adding a medium (proliferation medium) containing 10% FBS and 1% P / S in DMEM, followed by centrifugation at 1,000 g for 5 minutes. After centrifugation, the supernatant was discarded, and the remaining cell layer was suspended by adding a proliferation medium containing 20% FBS, 1% P / S, and 5 ng / mL FGF2 (Fibroblast Growth Factor 2) in Ham's F-10, followed by placing the cells on a collagen-coated cell culture dish and culturing at 37°C.
[0073]
[0074] [Experimental Example 8] Analysis of Muscle Cell Proliferation and Differentiation
[0075] 8-1. Muscle cell proliferation analysis
[0076] To determine the effect of Lic A on muscle cell proliferation, C2C12 cells were cultured in DMEM containing 10% FBS and 1% P / S, and the cells (2 × 10 3(cells / mL) were placed in a 12-well plate and allowed to attach for 24 hours, then treated with Lic A (1 ng / mL) for 1 day, and MTS assay was performed to analyze cell proliferation. For the MTS assay, the intracellular culture medium was removed, proliferation medium containing CellTiter 96 Aqueous One Solution Reagent was added, and the cells were incubated in a CO2 incubator at 37°C for 1 hour. After 1 hour, the absorbance was measured at 490 nm.
[0077]
[0078] 8-2. Muscle cell differentiation
[0079] To determine the effect of Lic A on muscle cell differentiation, when mouse muscle stem cells or C2C12 cells reached 100% growth, the cells were differentiated by treating them with differentiation medium (DMEM + 2% FBS + 1% P / S) and Lic A (1 ng / mL) for 2 days (mouse muscle stem cells) or 4 days (C2C12 cells).
[0080]
[0081] 8-3. Muscle cell differentiation analysis
[0082] For cell differentiation analysis, the medium was removed and C2C12 cells were washed with saline. PBS (200 ㎕ saline / 6-well plate) was added to the washed cells, the cells were scraped, sonicated, centrifuged (10,000 g, 5 min), and the supernatant was collected in a new tube. For creatine kinase activity analysis, a mixture of enzyme, substrate, and buffer (reaction: 1 ㎕ enzyme + 10 ㎕ substrate + 100 ㎕ buffer) was mixed with 10 ㎕ of sample (supernatant collected by centrifugation after collecting cells), and left to stand. The absorbance at 340 nm was measured at 20 and 25 minutes after the start of the reaction, and the creatine kinase activity value (U / L) was calculated using the following mathematical equation 1. After calculation, the value without any treatment was set as 100%, and the relative value of cells treated with Lic A was calculated.
[0083] [Mathematical Formula 1]
[0084] Creatine kinase activity (U / L) = [(25-minute OD value - 20-minute OD value) / (calibrator OD value - distilled water OD value)] × 600
[0085]
[0086] [Experimental Example 9] RNA extraction and cDNA synthesis
[0087] 1 mL of TRIzol™ reagent was added, and cells were disrupted using a sonicator. The disrupted cells were centrifuged (12,000 rpm, 10 min, 4°C), the supernatant was transferred to a new tube, 200 μl of chloroform was added, and the tube was left at room temperature for 10 min. After 10 min, centrifugation was performed (12,000 rpm, 10 min, 4°C) to obtain a transparent supernatant. After that, 500 μl of isopropanol was added, left for 10 min, and centrifuged to obtain an RNA pellet. The RNA pellet was washed with 70% ethanol [ethanol + distilled water treated with diethylpyrocarbonate (DEPC)], completely removed, and dried. The dried, transparent RNA was added to DEPC-treated distilled water and stored at -80°C. The total RNA amount was measured using a Nanodrop. cDNA was synthesized using 2 μg of total RNA, random hexamer primers, and reverse transcriptase (25°C for 10 min, 37°C for 120 min, and 85°C for 5 min).
[0088]
[0089] [Experimental Example 10] Analysis of Muscle-Related Factor Expression
[0090] 10-1. Gene expression analysis
[0091] To determine the effect of Lic A on the gene expression of muscle-related factors, real-time PCR was performed. Gene expression was analyzed using Power SYBR Green PCR Master Mix containing SYBR Green fluorescent material (7500 real-time PCR system). PCR primers were designed using Primer 3 software (http: / frodo.wi.mit.edu) based on the nucleotide sequences obtained from NCBI GenBank. PCR was performed at 95°C for 10 min, followed by 40 cycles of 95°C for 33 s, 33 s according to the gene primer temperature (tm), and 72°C for 33 s. The c(t) value obtained through real-time PCR analysis was expressed as a fold change of 2- △△ Gene expression values were analyzed using the Ct formula. The gene expression value of cells not treated with Lic A was set to 1, and the gene expression value of cells treated with Lic A was calculated. When analyzing gene c(t) values, normalization was performed using the GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) gene. The sequences of the PCR primers are as shown in Table 1.
[0092] Primer(bp)온도(℃)ForwardReverseGAPDH155595'-tgctggtgctgagtatgtcg-3'5'-caagcagttggtggtacagg-3'MSTN163595'-acgctaccacggaaacaatc-3'5'-ggagtcttgacgggtctga g-3'MYL2177595'-aaagaggctccaggtccaat-3'5'-cctctctgcttgtgtggtca-3'MYH248595'-gggttccattgacattgacc-3'5'-agggccagtgtttcacattc-3'Atrogin1160595'-ttcagcag cctgaactacga-3'5'-tgaaagcttcccccaaagta-3'MuRF1206595'-tgaggtgcctacttgctcct-3'5'-tcacctggtggctattctcc-3'ACVRIIB197595'-aacttccagagagacgcctt-3'5'-atcg tgggcctcatcttctt-3'Ki67247595'-cagacttgctctgggcctacc-3'5'-gccgttccttgatgattgtc-3'CyclinA2227595'-ctgtctctttacccggagca-3'5'-agtgatgtctggctgcctct-3'MSTN : myostatinMYL2 : myosin light chain 2MYH : myosin heavy chainMuRF1 : muscle RING-finger protein-1
[0093]
[0094] 10-2. protein expression analysis 1
[0095] To determine the effect of Lic A on the protein expression of muscle-related factors, Western blot analysis was performed. C2C12 cell media was removed and washed with PBS. The washed cells were then incubated with RIPA buffer and protease inhibitors, centrifuged at 12,000 rpm for 10 minutes, and the proteins contained in the supernatant were collected. Forty to sixty micrograms of the extracted protein was electrophoresed on an 8 to 10% acrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane (Milipore). The membrane was blocked with 3% skim milk or bovine serum albumin (BSA) for 1 hour at room temperature. Afterwards, primary antibodies (MYL2; 1:1000, MYH; 1:500, MSTN; 1:1000, Atrogin1; 1:500, MuRF1; 1:500, ACVRIIB; 1:500, Ki67; 1:500, Cyclin A2; 1:500, and ß-actin: 1:1000) diluted in 1% skim milk or BSA were added and incubated at 4°C for more than 16 hours. After 16 hours, the sections were washed three times with TBST (Tris-Buffered Saline containing Tween 20), and HRP (horseradish peroxidase)-conjugated secondary antibodies were reacted for 1 hour at room temperature. These were washed three times with TBST, and Super Signal West Pico Chemiluminescent Substrate was added and developed.
[0096]
[0097] 10-3. Protein Expression Analysis 2
[0098] To determine the effect of Lic A on the protein expression of muscle-related factors, immunocytochemistry was performed. The cultured C2C12 cells were cultured with the medium removed and washed once with PBS. The washed cells were fixed with 4% formaldehyde (Sigma) for 15 minutes, washed with PBS, and 0.2% tryptone X-100 (Sigma) was added and incubated for 5 minutes. The cells were washed again with saline, and 1% normal goat serum was added and incubated for 30 minutes. The primary antibodies (MYL2 and MYH, 1:50) were added and reacted at 4°C for 14 hours. The antibodies were removed, washed three times with PBS for 10 minutes each, and the cells were incubated with the secondary antibody (Alexa Fluor 488 goat anti-Mouse & rabbit SFX kit) for 1 hour. After 1 hour, the antibody was removed, the cells were washed with PBS for 10 minutes, the nuclei were stained with DAPI (4′,6-diamidino-2-phenylindol), and protein expression was observed using a fluorescence microscope.
[0099]
[0100] [Experimental Example 11] Statistical Analysis
[0101] The significance of differences between the means of normalized gene expression was determined using Tukey's Honestly Significant Difference (HSD) and the t-test. GAPDH was used as an internal control, and statistical analysis was performed using SAS version 9.0. A value of p ≤ 0.05 was considered statistically significant.
[0102]
[0103] [Example 1] Analysis of the interaction between LiCa, MTSN, and ACVRIIB
[0104] To determine the effect of Lic A on the binding efficiency of the receptors ACVRIIB and MSTN, molecular docking of MSTN and Lic A was performed, and protein-protein docking of the docked complex with ACVRIIB was performed. As a result, as shown in Fig. 1, the binding energy of the MSTN+Lic A complex was -6.9 kcal / mol, the binding energy of the MSTN+ACVRIIB complex was -59.97 kcal / mol, and the binding energy of the MSTN+ACVRIIB+Lic A complex was -52.71 kcal / mol.
[0105]
[0106] [Example 2] Analysis of the effects of LicA in normal muscle tissue and muscle stem cells.
[0107] Mice were orally administered Lic A for 11 days, and after H&E, phalloidin, and laminin staining, muscle fiber diameter was measured and muscle-related factor protein expression was analyzed. As shown in Figures 2A–2C, the Lic A-treated group (126.9 μm) showed increased muscle fiber diameter compared to the control group (untreated group, 101.5 μm), and the protein expression of MSTN, ACVRIIB, Atrogin1, and MuRF1 was decreased.
[0108] Furthermore, to confirm the effect of Lic A on mouse differentiation, mouse muscle stem cells were isolated and cultured for 2 days in differentiation medium containing Lic A during differentiation induction, and then the expression of muscle-related factors was analyzed. As a result, as shown in Fig. 2D, it was confirmed that Lic A suppressed the gene and protein expression of MSTN, Atrogin1, and MuRF1, and promoted the gene and protein expression of MYH.
[0109]
[0110] [Example 3] Analysis of muscle cell proliferation and differentiation
[0111] 3-1. Muscle cell proliferation analysis
[0112] To determine the effect of Lic A on muscle cell proliferation, C2C12 cells were cultured in a Lic A-containing growth medium for one day, and cell proliferation and muscle-related factor expression were analyzed. As shown in Figure 3, Lic A promoted cell proliferation and the gene and protein expression of Ki67 and Cyclin A2, and suppressed the gene and protein expression of MSTN, Atrogin1, and MuRF1.
[0113]
[0114] 3-2. Muscle cell differentiation analysis
[0115] To determine the effect of Lic A on muscle cell differentiation, C2C12 cells were cultured in differentiation medium containing Lic A for 4 days. As shown in Fig. 4, it was confirmed that Lic A promoted creatine kinase activity and MYL2 and MYH expression, and suppressed the expression of MSTN, Atrogin1, and MuRF1.
[0116]
[0117] 3-3. Analysis of Aged Muscle Cell Proliferation
[0118] To determine the effect of Lic A on the proliferation of aged muscle cells, C2C12 cells were cultured with ceramide (50 μM) for 2 days and then subcultured. One day after subculture, Lic A was treated, proliferation was allowed, and cell proliferation and muscle-related factor expression were analyzed. As shown in Figure 5, Lic A promoted cell proliferation and suppressed the gene and protein expression of MSTN, Atrogin1, and MuRF1.
[0119]
[0120] 3-4. Analysis of the muscle cell proliferation effect of LicC
[0121] To compare the muscle cell proliferation effects of Lic A and Lic C, C2C12 cells were cultured in a proliferation medium containing Lic C for one day, and cell proliferation was measured using an MTS assay. As a result, as shown in Fig. 6A, Lic C did not exhibit a significant effect on muscle cell proliferation.
[0122] In addition, to confirm the muscle cell differentiation effect of Lic C, C2C12 cells were cultured in differentiation medium containing Lic C for 4 days and creatine kinase activity was analyzed. As a result, as shown in Fig. 6B, it was confirmed that Lic C inhibited creatine kinase activity by approximately 8.5%. From the above results, it was confirmed that Lic C did not show a significant effect on muscle cell proliferation, but inhibited muscle cell differentiation.
[0123]
[0124] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. In other words, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A pharmaceutical composition for preventing or treating muscle disease, comprising licochalcone A as an active ingredient.
2. A pharmaceutical composition according to claim 1, wherein the licochalcone A promotes proliferation of myoblasts, formation of myotubes, or differentiation into muscle cells.
3. A pharmaceutical composition according to claim 1, wherein the licochalcone A promotes creatine kinase activity.
4. A pharmaceutical composition according to claim 1, wherein the licochalcone A is characterized by promoting the expression of at least one selected from the group consisting of Ki67, Cyclin A2, MYL2 (myosin light chain 2), and myosin heavy chain.
5. A pharmaceutical composition according to claim 1, wherein the licochalcone A inhibits the expression of at least one selected from the group consisting of myostatin, Atrogin 1, ACVRIIB (Activin receptor type-2B), and MuRF (muscle RING-finger protein-1).
6. A pharmaceutical composition according to claim 1, characterized in that the muscle disease is at least one selected from the group consisting of muscular atrophy, muscular dystrophy, sarcopenia, myopathy, myasthenia, and muscular injury.
7. A health functional food composition for preventing or improving muscle disease, comprising licochalcone A as an active ingredient.
8. A composition for promoting differentiation of myoblasts or muscle stem cells into muscle cells, comprising licochalcone A as an active ingredient.
9. A method for promoting differentiation of myoblasts or muscle stem cells into muscle cells, comprising a step of treating a non-human organism with licochalcone A.
Citation Information
Patent Citations
The method for extrection of non-polar componentsincluding licochalcone a by thermal processing andsolvent
KR100645994B1
Anti-inflammatory composition containing licochalcone a
KR1020100077553A
Chalcone compounds as activators of DDAH promoter from Glycyrrhiza uralensis and compositions for prevention and treatment of islet cellular apoptosis and diabetic nephropathy ...
KR1020100135424A
Extraction of functional components from glycyrrhiza inflata and use of its extract
KR1020120107652A
Mask having body temperature monitor function
KR1020220060123A
